Meyskens, Frank L. - University of California, Irvine - Department of Biological Chemistry

研究领域

We are studying the basis of drug resistance of melanoma cells with a particular interest in Ref-1/APE and redox regulation. We have also proposed an alternative model for the etiology and progression of cutaneous melanoma based on the altered redox metabolism in human melanoma cells and developed new anticancer therapies based on these observations. We are heavily involved in Phase I, II, and III clinical chemoprevention trials involving oral, colon, pancreas cancer, and melanoma and study such compounds as difluromethiornithine, Bowman-Birk Inhibitors (a Soybean-derived compound) SAMe, and Lovastatin.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Gerner E.W., Meyskens F.L., Jr. Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res. 2009 Feb 1;15(3):758-61. Review McEligot, A.J., Yang, S., Meyskens, F.L., Jr. Redox regulation by intrinsic species and extrinsic nutrients in normal and cancer cells. Annu. Rev. Nutr. 25:261-95, 2005 Yang, Z., Yang, S., Minser, B.J., Chiu, R., Liu, F., Meyskens, F.L., Jr. Nitric oxide initiates progression of human melanoma via a feedback loop medited by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol. Mol Cancer Ther. 2008 Dec;7(12):3751-60. Meyskens, F.L., Jr., McLaren, C.E., Pelot, D., Fujikawa-Brooks, S., Carpenter, P., Hawk, E., Kelloff, G., Lawson, M.J., Kidao, J., McCracken, J., Albers, C.G., Ahnan, D.J., Turgeon, D.K., Goldschmid, S., Lanoe, P., Hagedorn, C.H., Gillan, D.L., Gerner, E.W.: Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A randomized placebo-controlled, Double-Blind Trial. Cancer Prev Res June 1:15-32, 2008